BRIEF-Labopharm receives notice of ANDA submission for Oleptro generic

Nov 12 (Reuters) - Labopharm Inc: * Submitted ANDA for approval to market 150 and 300 mg generic versions of oleptro in the u.S. * Receives notice of ANDA submission with paragraph IV certification for generic of Oleptro * Says is currently reviewing the notice letter to determine next steps in this matter * Says received notice from Actavis South Atlantic Llc ((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780)) (For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved.

The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.